Skip to main content

Table 2 Demographic and clinical features of control groups

From: Ceruloplasmin functional changes in Parkinson’s disease-cerebrospinal fluid

  H PN
  Sex Age at examination [C] mg/ml Sex Age at examination [C] mg/ml Diagnosis
#1 F 70 0.34 F 50 0.23 pnp-infl
#2 M 72 0.32 F 60 0.35 pnp-infl
#3 M 76 0.36 F 69 0.75 pnp-infl
#4 F 43 0.21 M 46 0.45 pnp-idio
#5 M 54 0.25 M 75 0.26 pnp-infl
#6 M 72 0.27 M 50 0.58 pnp-infl
#7 M 46 0.47 M 80 0.41 pnp-idio
#8 F 62 0.34 F 39 0.41 pnp-infl
#9 M 78 0.53 M 31 0.77 pnp-infl
#10 F 59 0.35 M 35 0.51 pnp-tox
#11 M 81 0.47 F 64 0.32 pnp-tox
#12 M 76 0.52     
#13 M 82 0.43     
#14 F 69 0.28     
#15 M 73 0.57     
#16 F 78 0.77     
  10 M/6 F 68.2 ± 12 0.41 ± 0.15 6 M/5 F 54.5 ± 16.4 0.46 ± 0.18  
   m ± sd m ± sd   m ± sd m ± sd  
  1. H = healthy subjects; PN = peripheral neuropathies; [C] mg/ml = CSF total protein concentration; m = mean; sd = standard deviation; pnp-infl = peripheral neuropathy inflammatory; pnp-idio = pnp-idiopathic; pnp-tox = pnp-toxic